Cell and Gene Therapies

Apr 17, 2018
By BioPharm International Editors
The company is launching a new pre-fabricated, ready-to-run manufacturing facility that is expected to significantly decrease the production timeline for viral vector-based therapeutics.
Apr 16, 2018
By BioPharm International Editors
Sartorius Stedim Biotech will supply equipment for Penn State’s new Fermentation Facility in the university’s Center of Excellence in Industrial Biotechnology.
Apr 10, 2018
By BioPharm International Editors
The new 300,000-square-foot facility is considered the largest dedicated cell and gene therapy manufacturing facility with fully integrated services.
Apr 09, 2018
By BioPharm International Editors
Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.
Mar 29, 2018
By BioPharm International Editors
The companies will co-develop and co-promote a CAR T cell therapy in the United States.
Mar 26, 2018
By BioPharm International Editors
Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.
Mar 26, 2018
By BioPharm International Editors
The agreement gives IncoCell Tianjin, a wholly-owned subsidiary of China-based Boyalife Group, access to Cesca’s celluar processing contract development and manufacturing services.
Mar 23, 2018
By BioPharm International Editors
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
Feb 21, 2018
By BioPharm International Editors
The companies have partnered to develop and commercialize vectorized antibodies against tau for Alzheimer's and other neurodegenerative diseases.
Feb 12, 2018
By BioPharm International Editors
The companies have been awarded a collaborative grant of £1.9 million (US$2.6 million) from Innovate UK.
native1_300x100
lorem ipsum